GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » FCF Margin %

SLXN (Silexion Therapeutics) FCF Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Silexion Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Silexion Therapeutics's Free Cash Flow for the three months ended in Sep. 2024 was $-2.67 Mil. Silexion Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Silexion Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Silexion Therapeutics's current FCF Yield % is -130.42%.

The historical rank and industry rank for Silexion Therapeutics's FCF Margin % or its related term are showing as below:


SLXN's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -145.32
* Ranked among companies with meaningful FCF Margin % only.

Silexion Therapeutics FCF Margin % Historical Data

The historical data trend for Silexion Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silexion Therapeutics FCF Margin % Chart

Silexion Therapeutics Annual Data
Trend Dec22 Dec23
FCF Margin %
- -

Silexion Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Margin % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Silexion Therapeutics's FCF Margin %

For the Biotechnology subindustry, Silexion Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silexion Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silexion Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Silexion Therapeutics's FCF Margin % falls into.


Silexion Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Silexion Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-4.541/0
= %

Silexion Therapeutics's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-2.669/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silexion Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Silexion Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Silexion Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » FCF Margin %
Comparable Companies
Traded in Other Exchanges
N/A
Address
2 Ha mayan Street, Modi in-Maccabim-Reut, ISR, 7177871
Website
https://www.silexion.com
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.